Remove 2022 Remove Compounding Remove Pharmaceutical Companies
article thumbnail

Pharmaceutical microbiology: key developments 2022

European Pharmaceutical Review

This Q&A covers the key developments in pharmaceutical microbiology in 2022, featuring insight from pharmaceutical microbiology experts: Dr Tim Sandle, Head of Microbiology, Bio Products Laboratory Limited. Regulation, particularly Annex 1, was identified as a key focus for 2022.

Vaccines 128
article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 Europe’s position in the global pharmaceutical packaging and labelling market The authors highlighted that Europe led the worldwide market at 27 percent in 2022.

Packaging 118
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

France gets new sterile liquid drug manufacturing facility

European Pharmaceutical Review

The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs). Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies.

article thumbnail

Formulation development outsourcing market to be worth over $60bn by 2030

European Pharmaceutical Review

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent from its 2022 value of $35.1 Pharmaceutical companies globally are significantly investing in R&D. percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide.

article thumbnail

Biopharmaceuticals contributing to manufacturing outsourcing trend

European Pharmaceutical Review

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 percent between 2022-2030. Yet large companies are set to expand the market at a higher CAGR of 9.1

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. Green Chemistry in the Synthesis of Pharmaceuticals.

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

Last year, IQVIA predicted that 2022 would be the crunch year for Alzheimer’s therapies: it is with a sense of déjà vu that the exact same prediction is contemplated for 2023. The European Medicine Agency-approved Biomarin’s Haemophilia A gene therapeutic, Roctavian, in 2022, and it is expected to be approved by the FDA in 2023.

FDA 93